Navigation Links
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
Date:7/27/2009

- Management to discuss second quarter financial results -

LAVAL, QC, July 27 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Friday, August 7, 2009 at 8:30 a.m. (ET) to discuss its second quarter 2009 financial results. Labopharm will report its second quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21311012 followed by the number sign.

A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labophar
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
2. Labopharm amends debt facility agreement with Hercules
3. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
4. Labopharm Reports Results for First Quarter Fiscal 2009
5. Labopharm announces details for first quarter results conference call and annual meeting
6. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
7. Labopharm to present at Cowen 29th Annual Health Care Conference
8. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
9. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)
10. Labopharm to host conference call to discuss FDA approval of once-daily RYZOLT(TM) on Tuesday, January 6, 2009 at 8:30 a.m. (ET)
11. Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013 Indosoft Inc., developers ... for Asterisk, announced today the availability of ... enhancement offers improved options for extracting, consolidating and ... effective contact center management. , Large Asterisk based ... as it happens from the call center software. ...
(Date:6/19/2013)... BEACH, Florida (PRWEB) June 19, 2013 ... an emphasis upon crystal meth addiction treatment, helping men ... this powerful drug. , Crystal meth is a stimulant ... manufactured. The drug is most commonly smoked, but it ... It is commonly created in homemade labs using common ...
(Date:6/19/2013)... June 19, 2013 CoachingWebsites, ... for coaches, announced today its affiliation with ... will offer exclusive websites and marketing solutions and ... “This new partnership with Active Intelligence shows our ... to its fullest,” says Greer Van Dyck, Online ...
(Date:6/19/2013)... The US Drug Watchdog says, ... specifically designed to help a recipient of a DePuy Pinnacle ... elevated levels of cobalt, and chromium, because we believe this ... device is doing. In the event the cobalt, or chromium ... the person will need to consider, including possible revision surgery ...
(Date:6/19/2013)... 19, 2013 The Mesothelioma Victims ... Control of the 2500 to 3000 citizens, who will ... mesothelioma this year, about one third will be US ... diagnosed with this asbestos exposure form of cancer, or ... access to the nations most skilled mesothelioma compensation settlement ...
Breaking Medicine News(10 mins):Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2Health News:Crystal Meth Addiction Treatment and Crystal Meth Drug Rehab Announced by Recovery Associates 2Health News:CoachingWebsites (Websites for Coaches) Announces Their Partnership With Active Intelligence, LLC 2Health News:US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For Instant Access To The Nation's Top Asbestos Lawyers-Better Compensation 3
... the leading cause of visual impairment and blindness in ... people. ,The American Academy of Ophthalmology ... there are new treatments that can usually recover lost ... ,The Academy encourages those older than 50 ...
... men who become impotent after prostate cancer surgery may find ... the penis,// which assists in restoring the lost erectile function, ... findings came to light after a study of nearly 44 ... erectile function, following its loss after treatment for prostate cancer. ...
... caused by meningococcal infection and the disease spreads like wild ... of weeks in the late 1990s. Mortality rate in cases ... Patients also run a high risk of serious disability after ... each year 170,000 people around the world die of this ...
... breakfast was recalled from Singapore's markets as a precautionary ... that the product might be contaminated and cause botulism, ... were told to recall Earth's Best Organic 2 Apple ... from the Agri-Food and Veterinary Authority. ,The ...
... to a recent study published in February 21 Journal ... cancer// are at a higher risk of developing a ... for childhood cancer have resulted in a current overall ... shown that these survivors are specifically at a higher ...
... distress should be evaluated for primary ciliary dyskinesia, a ... fibrosis. ,According to Thomas Ferkol, M.D., ... that about 80 percent of patients with primary ciliary ... ,"The diagnosis of PCD requires a high ...
Cached Medicine News:Health News:Spring is Time for Age-Related Macular Degeneration (AMD) Awareness 2Health News:Survivors of Childhood Cancers at Higher Risk for Secondary Cancer 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 2Health News:Newborns With Respiratory Distress Potentially Have Rare Genetic Disease 3
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
(Date:6/18/2013)... , June 18, 2013  In a letter to ... , M.D., of Lake View, Iowa , ... receive annual influenza vaccine is neither scientifically justified nor ethically ... article in the summer issue of the Journal ... official statistics are correct, and an average of 36,000 patients ...
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... 18, 2011 Nile Therapeutics, Inc. (OTCQB: NLTX), ... heart failure patients, today announced that it has ... clinical trial evaluating pharmacokinetics (PK), pharmacodynamics (PD), safety ... of cenderitide in patients with chronic heart failure. ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... demonstrated in an IRB approved, randomized, placebo controlled, double-blinded ... has an impact on allergic rhinitis, a clinical condition ...
Cached Medicine Technology:Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 2Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 3Nile Therapeutics Completes Dosing of Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide in Chronic Heart Failure Patients 4Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 2Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™ 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: